Researchers tested opaganib in combination with standard hormone therapies in men with resistant prostate cancer. They ...

In the quest for optimal health, especially concerning prostate wellness, men often find themselves overwhelmed with options that claim to deliver results. This is where Total Control 24 comes into ...

In recent years, a new treatment strategy known as focal therapy (partial gland ablation) has emerged for prostate cancer considered to be “intermediate risk” — mostly, small tumors confined to one ...

Nocturia, a condition characterized by waking up multiple times during the night to use the bathroom, occurs in about one-third of men over the age of 30. As they age, men become even more likely to ...

At a median follow-up of 21.5 months, ADT plus apalutamide significantly prolonged median PSA progression-free survival compared with ADT monotherapy (24.9 vs 20.3 months; hazard ratio [HR], 0.52).

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...

Prostate cancer can come back, even after you've had treatment and your doctor declared you cancer-free. Prostate cancer that returns after treatment is called recurrent prostate cancer. Prostate ...

Testing for High-Risk Human Papillomavirus in Lower Genital Tract Tumors: If Knowledge Does Not Translate to an Action That Helps Patients—Why Do It? A substantial number of anticancer drugs receive ...

High-intensity focused ultrasound (HIFU) can help some men with prostate cancer avoid surgery or radiation. In recent years, a new treatment strategy known as focal therapy (partial gland ablation) ...